Helkroppsvibrasjoner for forbedring av helse og funksjon hos deltakere med kjemoterapi-indusert perifer nevropati
En ny terapeutisk intervensjon for å gjenopprette helse og funksjon hos personer med kjemoterapi-indusert perifer nevropati
This clinical trial studies how well whole body vibration works in improving the health and functioning of participants with chemotherapy-induced peripheral neuropathy. Peripheral neuropathy is a condition caused by exposure to chemotherapy drugs that may involve numbness/tingling and/or pain in the hands and feet, which can have adverse effects on daily life. Whole body vibration may cause weight loss and improve mobility and pain levels in cancer survivors who report symptoms of peripheral neuropathy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. Determine the feasibility and safety of whole body vibration (WBV) in adult cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).
II. Determine the effect of WBV training on physical functioning in adult cancer survivors with CIPN.
III. Explore the effect of WBV training on symptom relief (neuropathy symptoms, pain, fatigue) and readiness to exercise in adult cancer survivors with CIPN.
OUTLINE: Participants are randomized to 1 of 2 groups.
GROUP I (WBV): Participants complete two 10-minute WBV sessions per day, 7 days per week for 12 weeks.
GROUP II (USUAL CARE [UC]): Participants receive usual care and keep their same physical activity or dietary habits over 12 weeks.
After completion of study treatment, participants are followed up at 12 weeks.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Oregon
-
Portland, Oregon, Forente stater, 97239
- OHSU Knight Cancer Institute
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Histologically confirmed cancer stage I-IIIc (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
- Previous chemotherapy within five years of enrollment (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
- Presence of mild-very severe CIPN symptoms (confirmed by assessment using the Patient-Reported Outcomes [PRO]-Common Terminology Criteria for Adverse Events [CTCAE] criteria)
- Age 18 years or older at enrollment (confirmed by self-report on the Health History Questionnaire)
Exclusion Criteria:
- Body weight > 275 pounds (confirmed by self-report on the Health History Questionnaire)
- A medical condition, movement or neurological disorder, or medication use that contraindicates participation in low intensity exercise and/or WBV (confirmed by self-report on the Health History Questionnaire, and by physician clearance, if in the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone, contraindications other than those identified by the patient or physician are present, she may consider the participant ineligible.)
- Presence of any known metastases (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
- Adjuvant treatment for cancer within previous six weeks, other than hormone blocking, targeted or immunotherapy (confirmed by self-report on the Health History Questionnaire. If the patient is unable to confirm, we will send a letter to their physician to confirm for this criterion)
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Ingen inngripen: Usual Care (UC)
Participants randomly assigned to the UC group will serve as controls and will be tested at the same time points as the WBV group. The UC group will be asked not to change their physical activity or dietary habits across the intervention period and we will track any changes using a questionnaire. |
|
|
Eksperimentell: Whole body vibration (WBV)
Participants assigned to the WBV group will participate in twice daily 10-minute WBV training sessions, 7 days a week. Each WBV session will consist of a series of timed stands on the vibration platform (Marodyne LiV). During a timed stand, participants will perform slow controlled weight shifting exercises and gentle squats. The vibration frequency will be set at 30Hz and the amplitude set at 50-200 microns, for a total body acceleration of 0.4g+/-20%. |
Undergo WBV
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Accrual
Tidsramme: Up to 12-weeks
|
The number of participants enrolled during the recruitment period. |
Up to 12-weeks
|
|
Adherence
Tidsramme: Up to 12-weeks
|
Adherence = % of sessions attended and compliance = % of each session completed. |
Up to 12-weeks
|
|
Compliance
Tidsramme: Up to 12-weeks
|
Compliance = % of each session completed. |
Up to 12-weeks
|
|
Adverse events
Tidsramme: Weekly up to 12-weeks
|
An in-house survey will ask about adverse events (e.g., bone pain, nausea) that occur during the intervention. The number of discrete moderate and severe adverse events will be summed as a single variable. |
Weekly up to 12-weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective physical function
Tidsramme: 0, 12 weeks
|
Measured by the Physical Performance Battery (PPB) to determine a person's ability to perform daily tasks independently. The PPB consists of 3 timed tests: 5 repeated chair stands, standing balance, and gait speed over 4 meters. Each test is scored 0 (unable) to 4 (completes without difficulty), based on quartiles of performance, then scores are summed. The possible range of scores is 0-12. |
0, 12 weeks
|
|
Functional mobility
Tidsramme: 0, 12 weeks
|
Functional mobility will be measured by the Timed Up and Go (TUG) test which measures the time that it takes a person to rise from a chair, walk 7 m, turn around and return and sit in the chair. |
0, 12 weeks
|
|
Functional balance-sway velocity
Tidsramme: 0, 12 weeks
|
Functional balance will be measured by postural sway which evaluates how well a person can maintain their equilibrium during quiet standing. Will conduct a standard 30-second postural sway test to measure the sway velocity (m/s) during quiet standing with feet together and eyes closed using lightweight, inertial wireless sensors worn on the trunk. |
0, 12 weeks
|
|
Functional balance-sway area
Tidsramme: 0, 12 weeks
|
Functional balance will be measured by postural sway which evaluates how well a person can maintain their equilibrium during quiet standing. Will conduct a standard 30-second postural sway test to measure the sway area (m2/s3) of sway during quiet standing with feet together and eyes closed using lightweight, inertial wireless sensors worn on the trunk. |
0, 12 weeks
|
|
Functional balance-sway amount
Tidsramme: 0, 12 weeks
|
Functional balance will be measured by postural sway which evaluates how well a person can maintain their equilibrium during quiet standing. Will conduct a standard 30-second postural sway test to measure the amount (m/s2) of sway during quiet standing with feet together and eyes closed using lightweight, inertial wireless sensors worn on the trunk. |
0, 12 weeks
|
|
Symptoms of chemotherapy-induced peripheral neuropathy
Tidsramme: 0, 12 weeks
|
Chronic changes in symptoms will be assessed at 0 and 12 weeks using the Functional Assessment of Cancer Therapy Gynecologic Oncology Group Neurotoxicity (FACT/GOG-Ntx). The questionnaire consists of the 27 item FACT-G, plus 11 items that specifically measure chemotherapy-induced neuropathy symptoms and concerns. Higher scores indicate worse symptoms. |
0, 12 weeks
|
|
Fatigue Visual Analog Scale
Tidsramme: Before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
|
Fatigue overall will be measured both before and after each whole body vibration session using a visual analog scale to identify any acute symptom relief from training. The scale ranges from 0 (no fatigue) to 10 (worst fatigue). |
Before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
|
|
Patient Reported Outcomes Measurement Information System (PROMIS) fatigue scale
Tidsramme: 0, 12 weeks
|
Chronic changes in fatigue will be assessed using the PROMIS Fatigue Scale. This instrument includes 8 items rated on a 5 point scale from "not at all" to "very much". Higher scores indicate worse fatigue. |
0, 12 weeks
|
|
Pain Visual Analog Scale
Tidsramme: Before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
|
Pain in the feet will be assessed both before and after each session using a visual analog scale to identify any acute symptom relief from training. The scale ranges from 0 (no pain) to 10 (worst pain). |
Before and after every whole body vibration session, up to 2 times per day, 7 days per week, for 12 weeks
|
|
Brief Pain Inventory
Tidsramme: 0, 12 weeks
|
Chronic changes in pain will be assessed using the Brief Pain Inventory (BPI). The instrument has 2 subscales: pain severity and pain interference. Severity is determined by the average of 4 items rated from 0 (no pain) to 10 (pain as bad as you can imagine). Pain interference is determined by the average of 7 items rated from 0 (does not interfere) to 10 (completely interferes). |
0, 12 weeks
|
|
Body mass index
Tidsramme: 0, 12 weeks
|
Body mass index will be calculated as kg/m2. |
0, 12 weeks
|
|
Exercise readiness
Tidsramme: 1, 12 weeks
|
Exercise readiness will be assessed using the stage of change for exercise questionnaire. This is a categorical instrument with 5 options that indicate a person's readiness to engage in regular physical activity. Options that suggest engagement in more regular exercise are better. |
1, 12 weeks
|
|
Perceived physical function
Tidsramme: 0, 12 weeks
|
Perceived physical function will be measured by self-report using the Late-Life Function and Disability Instrument (LLFDI). |
0, 12 weeks
|
|
Gait
Tidsramme: 0, 12 weeks
|
The number of meters that participants can walk in 6-minutes will be recorded. |
0, 12 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Kerri Winters-Stone, PhD, OHSU Knight Cancer Institute
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Ernst M, Wagner C, Oeser A, Messer S, Wender A, Cryns N, Brockelmann PJ, Holtkamp U, Baumann FT, Wiskemann J, Monsef I, Scherer RW, Mishra SI, Skoetz N. Resistance training for fatigue in people with cancer. Cochrane Database Syst Rev. 2024 Nov 28;11(11):CD015518. doi: 10.1002/14651858.CD015518.
- Krasnow SM, Rubin CT, Roeland EJ, Horak FB, Stoyles SA, Dieckmann NF, Braun KN, Winters-Stone KM. Low-Intensity Vibration to Reduce Symptoms and Improve Physical Functioning in Cancer Survivors With Chemotherapy-Induced Peripheral Neuropathy: A Pilot Randomized Trial. JCO Oncol Pract. 2026 Jan;22(1):100-111. doi: 10.1200/OP-24-00961. Epub 2025 May 15.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- STUDY00018342
- STUDY00018342 (Annen identifikator: OHSU Knight Cancer Institute)
- NCI-2019-08961 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
What data in particular will be shared? All individual quantitative participant data collected during the trial, after deidentification.
What other documents will be available? None
With whom? Investigators who provide a methodologically sound proposal and complete a data sharing agreement that includes commitments to: (1) using the data only for research purposes and not to identify any individual participant, (2) securing the data using appropriate computer technology, and (3) destroying or returning the data after analyses are completed.
For what types of analyses? To achieve aims in the approved proposal.
IPD-delingstidsramme
Beginning 3 months following publication. No end date.
Tilgangskriterier for IPD-deling
Proposals should be directed to wintersk@ohsu.edu. To gain access to data, data requestors will need to sign a data sharing agreement and be approved to receive the data by the OHSU IRB.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .